295 related articles for article (PubMed ID: 25871394)
21. The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer.
Onstenk W; de Klaver W; de Wit R; Lolkema M; Foekens J; Sleijfer S
Cancer Treat Rev; 2016 May; 46():42-50. PubMed ID: 27107266
[TBL] [Abstract][Full Text] [Related]
22. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study.
Zapatero A; Gómez-Caamaño A; Cabeza Rodriguez MÁ; Muinelo-Romay L; Martin de Vidales C; Abalo A; Calvo Crespo P; Leon Mateos L; Olivier C; Vega Piris LV
Radiat Oncol; 2020 Jun; 15(1):137. PubMed ID: 32487218
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.
Čapoun O; Mikulová V; Jančíková M; Honová H; Kološtová K; Sobotka R; Michael P; Zima T; Hanuš T; Soukup V
Anticancer Res; 2016 Apr; 36(4):2019-26. PubMed ID: 27069196
[TBL] [Abstract][Full Text] [Related]
24. Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer.
Oeyen S; Liégeois V; De Laere B; Buys A; Strijbos M; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Dirix L
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):499-506. PubMed ID: 33230201
[TBL] [Abstract][Full Text] [Related]
25. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
26. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
Russo GI; Bier S; Hennenlotter J; Beger G; Pavlenco L; van de Flierdt J; Hauch S; Maas M; Walz S; Rausch S; Bedke J; Morgia G; Stenzl A; Todenhöfer T
BJU Int; 2018 Jul; 122(1):152-159. PubMed ID: 29542849
[TBL] [Abstract][Full Text] [Related]
27. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.
Danila DC; Anand A; Schultz N; Heller G; Wan M; Sung CC; Dai C; Khanin R; Fleisher M; Lilja H; Scher HI
Eur Urol; 2014 Jun; 65(6):1191-7. PubMed ID: 23954088
[TBL] [Abstract][Full Text] [Related]
28. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer.
Lin HM; Mahon KL; Weir JM; Mundra PA; Spielman C; Briscoe K; Gurney H; Mallesara G; Marx G; Stockler MR; PRIMe Consortium ; Parton RG; Hoy AJ; Daly RJ; Meikle PJ; Horvath LG
Int J Cancer; 2017 Nov; 141(10):2112-2120. PubMed ID: 28741687
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.
Pereira-Veiga T; González-Conde M; León-Mateos L; Piñeiro-Cid R; Abuín C; Muinelo-Romay L; Martínez-Fernández M; Brea Iglesias J; García González J; Anido U; Aguín-Losada S; Cebey V; Costa C; López-López R
Clin Exp Metastasis; 2021 Apr; 38(2):239-251. PubMed ID: 33635497
[TBL] [Abstract][Full Text] [Related]
30. Evolution of the Liquid Biopsy in Metastatic Prostate Cancer.
Moreno JG; Gomella LG
Urology; 2019 Oct; 132():1-9. PubMed ID: 31207303
[TBL] [Abstract][Full Text] [Related]
31. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
32. Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Chai S; Matsumoto N; Storgard R; Peng CC; Aparicio A; Ormseth B; Rappard K; Cunningham K; Kolatkar A; Nevarez R; Tu KH; Hsu CJ; Malihi P; Corn P; Zurita A; Hicks J; Kuhn P; Ruiz-Velasco C
Mol Cancer Res; 2021 Dec; 19(12):2036-2045. PubMed ID: 34462330
[TBL] [Abstract][Full Text] [Related]
33. Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression.
Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
Cancer Genomics Proteomics; 2015; 12(6):391-6. PubMed ID: 26543085
[TBL] [Abstract][Full Text] [Related]
34. Global gene expression profiling of circulating tumor cells.
Smirnov DA; Zweitzig DR; Foulk BW; Miller MC; Doyle GV; Pienta KJ; Meropol NJ; Weiner LM; Cohen SJ; Moreno JG; Connelly MC; Terstappen LW; O'Hara SM
Cancer Res; 2005 Jun; 65(12):4993-7. PubMed ID: 15958538
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumour cells-monitoring treatment response in prostate cancer.
Miyamoto DT; Sequist LV; Lee RJ
Nat Rev Clin Oncol; 2014 Jul; 11(7):401-12. PubMed ID: 24821215
[TBL] [Abstract][Full Text] [Related]
36. Expression profiling of circulating tumor cells in metastatic breast cancer.
Lang JE; Scott JH; Wolf DM; Novak P; Punj V; Magbanua MJ; Zhu W; Mineyev N; Haqq CM; Crothers JR; Esserman LJ; Tripathy D; van 't Veer L; Park JW
Breast Cancer Res Treat; 2015 Jan; 149(1):121-31. PubMed ID: 25432738
[TBL] [Abstract][Full Text] [Related]
37. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.
Kani K; Malihi PD; Jiang Y; Wang H; Wang Y; Ruderman DL; Agus DB; Mallick P; Gross ME
Prostate; 2013 Feb; 73(3):306-15. PubMed ID: 22911164
[TBL] [Abstract][Full Text] [Related]
38. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.
Miyamoto DT; Lee RJ; Kalinich M; LiCausi JA; Zheng Y; Chen T; Milner JD; Emmons E; Ho U; Broderick K; Silva E; Javaid S; Kwan TT; Hong X; Dahl DM; McGovern FJ; Efstathiou JA; Smith MR; Sequist LV; Kapur R; Wu CL; Stott SL; Ting DT; Giobbie-Hurder A; Toner M; Maheswaran S; Haber DA
Cancer Discov; 2018 Mar; 8(3):288-303. PubMed ID: 29301747
[TBL] [Abstract][Full Text] [Related]
39. Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility.
Pantel K; Hille C; Scher HI
Clin Chem; 2019 Jan; 65(1):87-99. PubMed ID: 30602476
[TBL] [Abstract][Full Text] [Related]
40. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer.
Faugeroux V; Lefebvre C; Pailler E; Pierron V; Marcaillou C; Tourlet S; Billiot F; Dogan S; Oulhen M; Vielh P; Rameau P; NgoCamus M; Massard C; Laplace-Builhé C; Tibbe A; Taylor M; Soria JC; Fizazi K; Loriot Y; Julien S; Farace F
Eur Urol Oncol; 2020 Aug; 3(4):498-508. PubMed ID: 31412010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
